Generic Pravastatin Reaches Market With Teva ANDA Approval
This article was originally published in The Tan Sheet
Executive Summary
Watson is launching its authorized generic version of Bristol-Myers Squibb's Pravachol (pravastatin) following FDA approval April 24 of Teva's ANDA to market the 10 mg, 20 mg and 40 mg doses of the drug